Do amyloid-targeting monoclonal antibodies (mAbs) exhibit varying efficacy between males and females?

From the Research

Amyloid monoclonal antibodies do not have established varying efficacy between sexes based on the provided evidence. The most recent and highest quality study, 1, discusses the current landscape and future perspectives of second-generation anti-amyloid monoclonal antibodies for Alzheimer's disease but does not mention sex-based differences in efficacy.

Key Points

• The provided studies focus on the mechanisms, outcomes, and limitations of second-generation anti-amyloid monoclonal antibodies for the clinical treatment of Alzheimer's disease.
• None of the studies directly compare the efficacy of amyloid monoclonal antibodies between sexes.
• The studies discuss the importance of targeting amyloid-β peptide, tau protein, and neuroinflammation in the treatment of Alzheimer's disease.
• The U.S. Food and Drug Administration has approved three anti-amyloid monoclonal antibodies, aducanumab, lecanemab, and donanemab, for the treatment of Alzheimer's disease.

Clinical Implications

• Clinicians should consider the potential benefits and risks of amyloid monoclonal antibodies when discussing treatment options with patients.
• Further research is needed to determine if there are any sex-based differences in the efficacy of amyloid monoclonal antibodies.
• The provided studies emphasize the importance of patient-centered informed decision-making and comprehensive discussions with patients and care partners regarding treatment expectations and potential risks.